Independent prognostic factors for event-free survival in randomized patients (n = 121)
Factor . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| Treatment arm | |||
| Prolonged vs standard treatment | 0.40 | 0.26-0.64 | < .0001 |
| Bcl-2 overexpression | |||
| Greater than 80% vs 80% or less | 0.55 | 0.34-0.87 | .01 |
| Monocyte count at baseline | |||
| 0.4×109/L or less vs greater than 0.4×109/L | 0.58 | 0.37-0.91 | .017 |
| Performance status at baseline | |||
| 0 vs 1 + 2 | 0.59 | 0.36-0.97 | .039 |
| Response to induction therapy | |||
| CR + PR vs SD + PD | 0.41 | 0.26-0.65 | .0001 |
Factor . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| Treatment arm | |||
| Prolonged vs standard treatment | 0.40 | 0.26-0.64 | < .0001 |
| Bcl-2 overexpression | |||
| Greater than 80% vs 80% or less | 0.55 | 0.34-0.87 | .01 |
| Monocyte count at baseline | |||
| 0.4×109/L or less vs greater than 0.4×109/L | 0.58 | 0.37-0.91 | .017 |
| Performance status at baseline | |||
| 0 vs 1 + 2 | 0.59 | 0.36-0.97 | .039 |
| Response to induction therapy | |||
| CR + PR vs SD + PD | 0.41 | 0.26-0.65 | .0001 |
CI indicates confidence interval; CR, complete response; PR, partial response; SD, stable disease; and PD progressive disease.